Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
San Miguel JF (1), Paiva B (2), Lasarte JJ (2).
(1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
(2) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
Magazine: Cancer Cell
Date: Sep 14, 2015Haematology and Hameotherapy
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors.
Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
CITATION Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.
you mayBE INTERESTED
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.